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Beyond Textbook: An Introduction 
Of the most important things I've learned at Regis, science came second. Science, 
in its beautiful complexity, was straightforward. For a nine-year-old just learning English, 
science was a language that I understood just as well as the other English-speakers. I did 
not come from a background that prepped me for reading, writing, or American history, 
but none of that mattered when I was conducting fourth-grade science experiments. I 
welcomed the sense of community I felt when I was immersed in science, and for the 
next ten years of my life, I made science my home. 
Nevertheless, like science, we all must evolve. In my elementary understanding of 
it, I saw science as a dissection of the world, a systematic way to break down, analyze, 
and define my surroundings. If science was a brick, I wanted to take my microscope and 
probe every detail of it. I was ready to commit the rest of my life to that one brick—to 
study it, to test it, to carve my initials onto every surface of it.  
In my four years here at Regis, I spent a lot of time studying bricks, both 
metaphorical and physical. When I was building houses in Pinellas County on a Habitat 
for Humanity trip last spring, I spent an entire week adding bricks to the exterior walls of 
half-finished houses. The bricks came in different shades of beige, cream, and brown, and 
it was up to our job to cement the slabs together to create a sturdy, reinforced wall. 
Alone, the bricks were not that useful, but when cemented together, they represented the 
boundaries of a small office, an outline of a private bedroom, or a framework of a future 
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dining area. Eventually, I learned that science was not much different from those concrete 
bricks in Pinellas County. Science, I came to accept, was a building block that helped 
support a larger, more important design.  
As my understanding of science matured, I recognized its applications in 
economics, healthcare, politics, and public regulations. In turn, these factors feedback to 
affect the current scientific research process we know today. Science cannot and should 
not be isolated to a single brick, because its significance protrudes into boundaries well 
outside of the scientific community. It is no longer satisfactory to simply study science 
without regard to the context in which the science is applied, which is why, for this 
thesis, I will also be exploring the history and impacts of federal regulations on scientific 
research. 
Science, while already a compelling field on its own, is exponentially more 
influential and intriguing when studied in context of a larger picture. This project, at its 
core, is an exploration of science and detail. For many reasons, the questions I’m 
exploring in this research needs to be asked. How does this Parkinson’s disease-fighting 
drug work? What does the drug do? How does it fight Parkinson’s disease? But even 
more importantly, we have to ask what this science means in the larger scope. How soon 
can the drug be used? What are the long-term side effects? And in what ways can it help 
people? Mirroring the way my education developed in my four years at Regis, this thesis 
will first explore the science behind the phenylbutyrate mechanism. Then, it will take a 
step back and put the science into the context of historical and current drug research 
policies, FDA regulations on drug development, and previous Parkinson’s disease 
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research in hopes of identifying potential directions of the phenylbutyrate drug. 
Like the Pinellas County brick, science belongs to a greater infrastructure. The 
brick is not meant to be broken down and studied on its own; instead, it should serve as a 
building block. I have learned engage with science, to chisel it and recognize the ways it 
influences and builds the world. After years of narrowing my research in the laboratory, 
I’m left to ask myself in what ways I can expand—and that, is beyond textbook. 
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CHAPTER 1: The History 
Parkinson’s Disease Research 
Parkinson’s disease was first described by James Parkinson in 1817, who depicted 
the condition as a shaking palsy syndrome (Goetz, 2011). He wrote of a slowly 
progressing ailment that initially caused a “slight sense of weakness” in patients who had 
“a prone to trembling… in the hands or arms” that eventually developed into a complete 
“submission of the limbs” (Freed & Levay, 2002, p. 7-9). “As the disease proceed[ed] 
towards its last stage”, he wrote, “the trunk is almost permanently bowed, the muscular 
power [was] more decidedly diminished, and the tremulous agitation becomes violent” 
(Freed & Levay, 2013, p. 7-9). Although Parkinson did not know what he was observing 
at the time, his strikingly accurate descriptions of the disease’s symptoms became the 
iconic snapshot of Parkinson’s disease for centuries to come.   
Now, Parkinson’s disease is known as one of the most common and devastating 
neurological disorders in the world. Currently, over 10 million people worldwide are 
living with Parkinson’s disease and as many as 60 million Americans are newly 
diagnosed each year (Parkinson’s Disease Foundation). The disease is a gradual, chronic, 
and progressive brain-degenerating condition characterized by uncontrollable tremors, 
stooped posture, and movement rigidity—archetypal symptoms that Parkinson depicted 
in his original writings (Fahn & Sulzer, 2004; Goetz, 2014). Sadly, the effects of 
Parkinson’s disease are not limited to just motor impairments. Later stages of the disease 
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results in mental decline such as dementia, impaired language, and decreased levels of 
higher reasoning (Aarsland et al., 2004; Goetz, 2011).  
Although James Parkinson’s essay was not recognized at the time of its 
publication, Jean-Martin Charcot reintroduced Parkinson’s disease in the 1870s after 
stumbling across James Parkinson’s old notes. With this, Charcot ignited a fascination for 
the shaking palsy. Almost immediately following Charcot’s publication, several 
researchers conducted separate long-term studies of Parkinson’s disease patients, 
reporting symptoms of the disease in its progressive stages (Freed & Levay, 2002; Goetz, 
2011). Soon after, scientists associated Parkinson’s disease with damages in the 
substantia nigra and the midbrain. Then, in 1960, Austrian scientist Oleh Hornykiewicz 
began measuring dopamine levels in postmortem Parkinson’s disease patients. He 
published an article six years later detailing the correlation between dopamine depletion 
in the substantia nigra and the motor deficits observed in Parkinson’s disease (Fahn, 
2008). From this moment forward, Parkinson’s disease and dopamine deficiency became 
irreversibly linked. 
We now know that Parkinson’s disease is induced by the death of dopamine-
releasing neurons in the substantia nigra, a region in the midbrain that plays an important 
role in movement control and fine motor coordination. When the chemical dopamine is 
released, it relays motor commands from the substantia nigra to the rest of the body. 
Without the message relay via dopamine, the body lacks the ability to inhibit 
inappropriate movements or initiate correct movements (Olanow, 2015). But despite the 
well-known importance of dopamine in motor control, the exact cause of the dopamine-
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releasing cell death was—and is—still unclear. However, by simply mapping the 
dopamine motor control pathway, Hornykiewicz introduced the possibility of a cure. He 
launched the world on a mission to find out why dopamine neurons were dying and what 
can be done to prevent such destructive cell death (Fahn, 2008; Freed & Levay, 2002; 
Goetz 2011). 
Up until Hornykiewicz, most of the pioneering research in Parkinson’s disease 
had been exploratory. However, as Parkinson’s disease research shifted towards a 
pharmacological path, researchers had to follow a different set of research regulations. 
During the time scientists were studying the long-term effects and clinical presentations 
of Parkinson’s disease in the late 1800s and early 1900s, both the United Kingdom and 
the United States began reforming their ethical standards for drug research (Rägo & 
Santoso, 2008). With the new revolutions in medicine and technology in the 1900s, there 
grew a need for government intervention to ensure public safety as new drugs entered the 
market in large quantities. The United Kingdom introduced the Committee of Drug 
Safety in 1963, and following that, a public drug adverse reaction reporting system. The 
United States, similarly, passed the Drug Amendments Act of 1962, stating that the 
government had to approve all new drugs entering the market (Rägo & Santoso, 2008). In 
terms of Parkinson’s disease research, this created restrictions for scientists who were 
looking for a cure to Parkinson’s disease. Not only was Parkinson’s disease research 
redirecting its focus for the first time towards treatment research, it was doing so under 
newly formed drug research guidelines. 
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During the time that these drug research regulations were forming, Hornykiewicz 
took his research into his own hands. After mapping out the dopamine motor pathway, 
Hornykiewicz speculated that replacing the brain’s depleted dopamine reserve could 
alleviate the motor symptoms of Parkinson’s disease (Freed & Levay, 2002). 
Unfortunately, the dopamine molecule itself was too big to enter the brain, so dopamine 
had to be replenished indirectly. Hornykiewicz theorized that its precursor, the smaller 
dihidroxyphenylalanine, or D,L-DOPA, was small enough to cross the blood-brain 
barrier. It then could be converted into dopamine once it reached the brain by the body’s 
natural enzymes (Fahn, 2008; Freed & Levay, 2002; Goetz 2011). In 1961, two years shy 
of the United Kingdom’s introduction of the Committee of Drug Safety, Hornykiewicz 
sent a vial of D,L-DOPA to his friend, Walther Birkmayer, a physician at a Viennese 
neurology facility, to test the effects of D,L-DOPA on the Parkinson’s disease patients 
housed at Birkmayer’s neurology facility (Fahn, 2008; Freed & Levay, 2002; Goetz 
2011).  
Without the scrutiny of government drug research regulations, Birkmayer 
administered D,L-DOPA to his late-stage Parkinson’s disease patients, taking advantage 
of their incapacitated states to test the effects of Hornykiewicz’ mystery drug. By today’s 
standards, this would have been a clear violation of research’s ethical code of conduct. 
Birkmayer did not know the drug’s side effects, did not perform safety checks on the 
drug, and did not test the drug on non-human models beforehand, but because those 
restrictions did not exist in 1961, neither Hornykiewicz or Birkmayer were held liable for 
their questionable research methods. But regardless of Birkmayer and Hornykiewicz’ 
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controversial protocols, their results changed the world. D,L-DOPA seemed to cure even 
the most severe cases of Parkinson’s disease, pulling bedridden patients back onto their 
feet once more (Freed & Levay, 2002; Goetz 2011). Perhaps a cure was possible after all.  
However, the drug was not perfect. After Birkmayer and Hornykiewicz published 
their findings, D,L-DOPA went under high levels of scientific scrutiny, partly influenced 
by the increasing standards of drug research and drug quality in the public market. For 
one, the right-hand versions of DOPA was toxic and produced horrible side effects, and 
only L hand DOPA, or L-DOPA, was actually helpful in alleviating Parkinsonian 
symptoms. Furthermore, subsequen studies showed that high doses of L-DOPA were 
needed before enough of the drug reached the brain to effectively treat Parkinsonian 
motor symptoms. Unfortunately, these high doses left large concentrations of the drug 
circulating inside the body, causing side effects such as nausea, vomiting, GI 
disturbances, dyskinesia, rashes, etc. (Fahn, 1999; Goetz, 2011). In response to this, later 
versions of L-DOPA treatments were mixed with carbidopa, a dopa decarboxylase 
inhibitor, to delay the conversion of L-DOPA to dopamine until after L-DOPA passed the 
blood brain barrier and increase the percentage of the drug that reached the brain (Fahn, 
1999; Goetz, 2011).  
Even after the Carbidopa/L-DOPA combination (commonly marketed as 
Sinemet), the drug was not still not foolproof, continuing to produce side effects with 
prolonged use. In the U.S., the first recorded review of Sinemet by the FDA was in 1977, 
but since its introduction, Sinemet’s dosing, labeling, manufacturing has been adjusted 
over 50 times with the last FDA-published revision in 2015 (U.S. Food & 
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Administration, 2017). To this day, the carbidopa/L-DOPA combination continues to be 
frequently revised for better drug efficacy. Unfortunately, all research thus far seems to 
suggest that L-DOPA therapy is not a permanent fix for Parkinson’s disease (Fahn, 1999; 
U.S. Food & Administration, 2017).  
Over the years, the climate of Parkinson’s disease research evolved. For one, as 
Parkinson’s disease research evolved, so did government standards for conducting 
research, impacting the way Parkinson’s disease research can be carried out, especially in 
the United States. Secondly, there was a push to move away from L-DOPA, since it 
became widely known as merely a temporary solution for an irreversibly progressive 
problem. Instead, research began exploring gene therapy, misfolded protein targets, and 
alternative drugs as potentially better treatments for Parkinson’s disease. My research, for 
example, investigates an alternative drug called phenylbutyrate that could prevent the 
onset and progression of Parkinson’s disease in the brain. To further explore this search 
for the cure, the next chapter of this thesis is a research paper that will highlight the 
process of new drug proposals, drug testing, and mapping of drug mechanisms to 
determine drug efficacy. Together, as research and research regulations developed side 
by side, it shaped the search to find a better cure for Parkinson’s disease.  
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II. CHAPTER 2: The Science 
Does TAF1 activity regulate DJ-1 gene production in response to phenylbutyrate 
treatment? 
Abstract 
Parkinson's disease is a disruptive brain-degenerating disease caused by aging, 
abnormal protein build-up in the brain, and genetic predisposition. While the drug L-
DOPA is currently the most effective treatment for Parkinson’s disease symptoms, long-
term use of the drug creates adverse effects. One alternative solution is to treat 
Parkinson’s disease at the genetic level. For example, malfunctions in the gene PARK7, 
or DJ-1, are associated with early-onset Parkinson's disease. On the other hand, 
enhancing production of the DJ-1 gene is protective against the development of 
Parkinson’s disease. In 2011, Zhou and colleagues found that treatment with a drug 
called phenylbutyrate increases DJ-1 gene production in neurons, thus protecting neurons 
from the onset of Parkinson’s by manipulating the protective genetic material already 
present in the normal cells. While the mechanism which the drug phenylbutyrate acts 
upon DJ-1 gene production remains unclear, previous research in the Freed lab shows 
that the Sp1 transcription factor, a protein on the DJ-1 promoter that initiates DJ-1 gene 
production when bound, activates in response to phenylbutyrate treatment. This protein 
activates through a method that adds an acetyl group to the Sp1 transcription factor, 
changing the transcription factor’s structure by switching it “on”. We believe that TAF1, 
a protein previously known to add acetyl groups to various other transcription factors, is 
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involved. To illustrate the importance of TAF1 activity in Sp1 activation, we treated cells 
with the drug phenylbutyrate and compared the response of cells without the TAF1 
proteins to normal cells with TAF1 proteins intact. However, there was no significant 
differences between TAF1-intact and TAF1-deficient cells. 
 
Research Introduction 
Currently, the most effective symptomatic treatment for Parkinson’s disease is L-
DOPA, a drug that is converted to dopamine in the brain to substitute for the dopamine 
loss that causes Parkinson’s disease. However, L-DOPA is not effective in long-term use 
as the body builds tolerance to increasing levels of the drug and because L-DOPA works 
by increasing dopamine production in existing dopamine neurons; as the dopamine 
neurons degenerate through the course of Parkinson’s disease, there are not enough 
dopamine neurons left for L-DOPA to target (Olanow, 2014). Additionally, studies 
suggest that levodopa has toxic effects after prolonged exposure, prompting researchers 
to pursue novel treatments for Parkinson’s disease (Lesser et al., 1979). 
One novel treatment approach is to manipulate the genetic components of the 
disease. Although the exact cause of dopamine cell death is still unclear, there are genetic 
components that predispose the onset of Parkinson’s disease (Fahn & Sulzer, 2004; 
Olanow, 2015). Severe cases of Parkinson’s disease are associated with many factors, 
including mutations in the PARK genes that cause the genes to stop working properly 
(Lücking et al., 2000; Mullin & Schapira, 2015). Particularly, mutations that damage the 
PARK7 gene, or the DJ-1 gene, are linked to early-onset, autosomal recessive forms of 
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Parkinson’s disease. On the other hand, increasing production of the DJ-1 gene has 
protective effects against the development of Parkinson’s disease (Inden et al., 2006). 
When neurons are exposed to a toxic chemical called 6-hydroxydopamine, a substance 
designed to mimic brain deterioration in Parkinson’s disease by selectively killing 
dopamine neurons, it stimulates DJ-1 production, which is able to increase the body’s 
natural defenses to preserve and save the brain cells (Zhou & Freed, 2005). 
If we can increase concentrations of the DJ-1 gene in a Parkinson’s disease 
patient, we potentially prevent the progression of the disease. Phenylbutyrate naturally 
boosts DJ-1 production. Phenylbutyrate increases DJ-1 by 300% in cultured neurons after 
48 hours of treatment and almost double in mice models after 3 months of treatment 
(Zhou et al, 2011).  In doing so, phenylbutyrate enhances DJ-1 protective properties, 
preventing dopamine neurons from dying even after exposure to toxic levels of oxidative 
stress.  
While phenylbutyrate is a promising drug for increasing cellular DJ-1 levels and 
for preventing the onset of Parkinson's disease, the mechanism which phenylbutyrate 
increases the DJ-1 gene production still remains unclear. My previous research in the 
Freed lab with dopamine neurons suggest that phenylbutyrate treatment activates the Sp1 
transcription factor, a protein that binds to the DJ-1 promoter to initiate the protein 
synthesis in the cell (Freed, 2016). Sp1 transcription factor activation occurs when Sp1 is 
acetylated, or when an acetyl group is added to Sp1 to change the transcription factor’s 
shape and turn it on. I was able to show that as the cells were treated with increasing 
phenylbutyrate concentrations, Sp1 acetylation increased correspondingly (Freed, 2016).  
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However, the rate of increased Sp1 transcription factor acetylation did not directly 
correlate with the concentrations of phenylbutyrate used, suggesting that there are 
intermediate steps in the mechanism. I believe that in one intermediate step, 
phenylbutyrate is attaching an acetyl group to the Sp1 transcription factor inside the cell. 
Recent studies show that TAF1 proteins assist Sp1 transcription factor acetylation and 
activation in cyclin D1 promoters of hamster cells. The TAF1 protein transfers acetyl 
groups from a donating molecule and attaches it to the Sp1 transcription factor, changing 
its shape and launching it into action. Moreover, in the absence of the TAF1 protein, Sp1 
transcription factor acetylation does not take place and gene production halts as the cyclin 
D1 promoter is not activated (Hilton & Wang, 2003; Hilton, Li, Dunphy, & Wang, 2005). 
Sp1 acetylation activated cyclin D promoter activity, but this mechanism is not 
necessarily universal to the DJ-1 gene promoter since every promoter is unique to the 
gene. Furthermore, Hilton, Li, Dunphy and Wang did not test the effects of Sp1 
acetylation in response to the phenylbutyrate drug.  
My thesis project expands on the findings of Hilton, Li, Dunphy, and Wang 
(2005), applying their TAF1 Sp1 transcription factor acetylation model to the context of 
DJ-1 gene production in response to phenylbutyrate. While their project largely 
investigated cellular reproduction as a whole, my project will specifically compare the 
levels of DJ-1 gene production in wild-type cells with intact TAF1 activity and mutant 
cells without the TAF1 activity, both before and after phenylbutyrate treatments. I want 
to isolate the effects of the phenylbutyrate drug on TAF1-dependent Sp1 acetylation and 
clarify the unknown steps of phenylbutyrate’s mechanism from my previous research. 
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Additionally, in the past, I studied the Sp1 acetylation in response to phenylbutyrate in 
dopamine neurons. In Hilton, Li, Dunphy, and Wang’s experiments and in this thesis 
project, I will use temperature-sensitive mutant cells, called ΔSTU, that retained normal 
TAF1 activity at low temperatures but turned off TAF1 activity at high temperature.  
I hypothesize that at low temperatures, because both the normal wild type and the 
mutant cells would be functioning regularly, phenylbutyrate will affect both the normal 
wild type and the mutant cells in the same way and increase DJ-1 gene production in both 
cell types. However, I predict that, at higher temperatures, phenylbutyrate will increase 
DJ-1 gene production in the normal wild-type cells, but not the mutant cells because the 
TAF1 activity in the mutant cells will have ceased under these conditions. Ideally, this 
project will illustrate the importance of TAF1 activity in Sp1 activation and DJ-1 gene 
production such that, without TAF1 activity, Sp1 activation and DJ-1 gene production 
will discontinue. My results will either reaffirm my proposition that phenylbutyrate 
acetylates the Sp1 promoter to increase DJ-1 gene production or offer a chance for us to 
readdress the mechanism on which phenylbutyrate acts on DJ-1 with a different 
approach. 
Method 
Culturing wild-type ts13 cells and mutant TAF1-deficient ts13 cells 
 Wild-type ts13 cells, or temperature-sensitive baby hamster kidney cells, exhibit 
late-stage cellular arrest at 39.5 °C such that the cells stop producing the materials 
necessary for continued growth and multiplication (Hilton, Li, Dunphy, & Wang, 2005). 
Additionally, mutants of the ts13 cells, ΔSTU ts13, turn off the TAF-1 genes above 37.5 
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°C. Essentially, at these temperatures, these cells are unable to make TAF-1 proteins and 
therefore cannot assist in acetylation activities. However, at a lower temperature of 33.5 
°C, TAF-1 protein functions are restored (Hilton, Li, Dunphy, & Wang, 2005).  
Both wild-type and mutant cell lines were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with L-glutamate, which has high concentrations of amino 
acids and vitamins to stimulate cell growth (Sigma Aldrich, 2016). Following the Wang 
lab’s protocol for optimal ts13 cell culture, we additionally added in 10% Hyclone Fetal 
Clone III as supplements for cell growth, 1% penicillin/streptomycin to reduce chances of 
bacterial contamination, and 2mM of L-glutamine with 200 µg/mL of G418 for added 
amino acid supplementation to increase the rates of cell growth (Thermo Scientific, 
2016). Both cell lines were incubated in 100 mm plates at 33.5 °C, 37.5 °C, and 39.5 °C 
for 72 hours before treatment. 
Phenylbutyrate treatment of wild-type and mutant ts13 cells 
 Wild-type and TAF-1 deficient mutant ΔSTU ts13 cells were treated with 150 µM 
of phenylbutyrate for 96 hours. 150-300 μM of phenylbutyrate most effectively increases 
DJ-1 production in rat dopamine neurons (Zhou et al., 2011). There are no reports of DJ-
1 expression in temperature-sensitive baby hamster kidney cells. 
Protein extraction and Western blotting 
After the wild-type and mutant ts13 cells were cultured and treated, they were 
scraped from culture plates, washed, and lysed using a buffer made of 50 mM Tris-Cl at 
pH 7.4, 10 mM NaCl, and 1% Tris, which induces rupture of the cell membrane for 
protein extraction. We additionally added a protease inhibitor tablet to protect the 
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proteins from degrading once they were removed from the cell (Thermo Scientific, 2016). 
Proteins were kept on ice during the extraction and were stored at -80˚C afterwards.  
We ran the proteins through an electric current and separated them by atomic 
molecular weight. We separated 40 μg of cellular protein on a 15-well 10% Mini Protean 
TGX gel. Proteins were then transferred to a nitrocellulose 0.45 µm membrane, a special 
paper that readily catches and holds on to protein. The membranes were incubated with 
rabbit DJ-1 antibody for a minimum of 12 hours. We added rabbit β-actin antibody as a 
loading control. Membranes were incubated with donkey anti-rabbit secondary antibodies 
for another 24 hours to amplify the first antibody signal.  
Western blotting quantification and statistical analyses.  
Western blots were scanned and quantified using ImageJ software. DJ-1 protein 
densities were normalized to the β-actin protein densities per sample to reduce 
background noise and protein loading errors. Each experiment was repeated at least 6 
times. Outliers were calculated and removed using the Thompson tau technique. The data 
was analyzed using a 3-way ANOVA in SPSS for significance and Eta-squared (ƞ2) 
measurement for effect size. Significance was set at p < 0.05. Values are shown as mean 
± SE (See Figure 1). 
Results 
 The averages and standard deviations of the protein band densities of the different 
cells, different culture temperatures, and different treatments are present in Table 1. 
There was a significant main effect of temperature on DJ-1 protein densities (F(2, 12) = 
6.62, p > .01, ƞ2 = .17) and there was a significant main effect of drug treatment on DJ-1 
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protein densities (F(1, 12) = 4.40, p = .04, ƞ2 = .06). However, there was no significant 
main effect of ts13 strain on the DJ-1 protein densities (F(1, 12) = 0.54, p = .47, ƞ2 = .01). 
Additionally, there was a significant interaction of ts13 strain and drug treatment on DJ-1 
protein densities (F(1, 12) = 5.21, p = .03, ƞ2 = .07). There was no significant interaction 
of ts13 strain and temperature on DJ-1 protein densities (F(2, 12) = 2.09, p = .132, ƞ2 = 
.06) and no significant interaction of temperature and drug treatment on DJ-1 protein 
densities (F(2, 12) = 0.47, p = .63, ƞ2 = .01). Finally, there was no significant interaction 
of ts13 strain, temperature, and drug treatment on DJ-1 protein densities (F(2, 12) = 
0.241, p = .79, ƞ2 = .01).  
Discussion 
 I hypothesized that at low temperatures, wild type and mutant cells would be the 
same and phenylbutyrate would be able to increase DJ-1 production in both cell lines. I 
also hypothesized that at higher temperatures, phenylbutyrate would increase DJ-1 in 
wild-type cells but not the mutant cells. My results only partially supported these 
hypotheses. In agreement with Zhou et al. (2005) and my initial predictions, treatment 
with the drug phenylbutyrate increased DJ-1 concentrations. Also in agreement with the 
original hypothesis, DJ-1 protein densities were lower at 39.5 °C than at 33 °C and at 
37.5 °C, suggesting that DJ-1 production may have been inhibited when TAF1 activity 
was turned off at high temperatures. Unfortunately, there was no main effect of cell type 
on DJ-1 concentrations, which indicates that cells with TAF1 activity and cells without 
TAF1 activity largely produced the same amount of DJ-1 protein densities.  
Mutant ts13 cells reportedly turned off TAF1 activity without affecting the large 
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remainder of cellular functioning. However, because the mechanism of how 
phenylbutyrate is increasing DJ-1 production is largely unclear, there is no way to ensure 
that inhibition of ts13 cell processes at high temperatures are not turning off other critical 
components of the phenylbutyrate mechanism at this time. As a result, differences 
between wild type and mutant ts13 cells may not be reliable. Additionally, errors in 
Western blot handling left background noises and air bubbles in the protein transfer, 
creating splotchy lanes (see Figure 2). These interferences, although small when looking 
at the blot, can amount to large differences in protein densities when examined with 
sensitive detecting equipment like ImageJ. For future technical changes, I will repeat the 
experiment with more trials and larger groups to improve the reliability of the results and 
minimize the differences due to Western blotting technique. 
In Wenbo and Freed’s experiments in 2005, DJ-1 production and its protective 
effects were stimulated when dopamine brain cells were stressed or exposed to toxic 
chemicals that threatened to kill the cell. In these experiments, the ts13 cells were not 
stressed because I originally thought that changes in temperature would be enough turn 
on or off cellular processes. Regrettably, this lack of stress could have affected the rate of 
DJ-1 production. Future replications of this experiment will include treatments of 
phenylbutyrate by itself and treatments of phenylbutyrate paired with the neurotoxin 6-
hydroxydopamine to maximize DJ-1 production. 
Similar to the Freed Lab’s previous experiments showing that phenylbutyrate 
increased Sp1 acetylation and with Hilton, Li, Dunphy, and Wang’s (2005) findings that 
showed TAF1 activity playing an important role in Sp1 acetylation, I was able to show 
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that phenylbutyrate increased DJ-1 protein concentrations and DJ-1 was more abundant 
at low temperatures. My results offer more insight to mapping out the mechanism in 
which phenylbutyrate increases the production of the DJ- gene. With this data, the Freed 
Lab further supports the benefits of phenylbutyrate against preventing Parkinson’s 
disease, building a stronger portfolio when they seek FDA approval for this drug. 
Evidently, phenylbutyrate is a revolutionary drug that has the potential to change the way 
we treat Parkinson’s disease. Hopefully with the FDA’s blessing, it will rightfully be 
available to the public in the near future.  
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Tables and Figures 
Table 1 
Average DJ-1 Protein Densities Normalized to β-Actin Control and Standard Deviations 
(SD) After Exposure to Different Temperatures and Phenylbutyrate (PB) treatments 
Temperature cultured 33°C 
n = 34 
37.5°C 
n = 33 
39.5°C 
n = 12 
Ts13 wild types − PB .62 (.35) 1.0 (.38) 1.1 (.39) 
Ts13 wild types + PB 1.2 (.53) 1.5 (.25) 1.3 (.82) 
TAF1-deficient mutants – PB .99 (.42) 1.4 (.34) .78 (.34) 
TAF1-deficient mutants + PB 1.03 (.50) 1.3 (.27) .76 (.74) 
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Tables and Figures 
 
Figure 1. Mean DJ-1 protein densities in wild type and mutant ts13 cells after normalized 
to β-actin control density bands. Cells were incubated with drug treatments for 72 hours. 
Error bars represent standard error. 
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Figure 2. Western blot depicting DJ-1 and β-actin protein bands from wild type and 
mutant ts13 cells treated after phenylbutyrate treatment. Cells were incubated at 37.5 °C 
prior to protein extraction. 
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Figure 3. Wild type ts13 cells after 72 hours of incubation with 150 µM phenylbutyrate. 
Cells were cultured at 37.5 °C. 
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III. CHAPTER 3: The miles left until FDA approval 
Developments in FDA and Drug Research 
As a student researcher investigating the potential use of phenylbutyrate in future 
treatments of Parkinson’s disease, I was introduced to the Food and Drug Administration 
(FDA) very early on in my project. The FDA is a branch of the U.S. Department of 
Health and Human Services that regulates the production, marketing, and distribution of 
food, drugs, biomedical devices, and consumer goods to protect Americans from harmful 
or misleading products (Hamburg & Sharfstein, 2009). Under President Theodore 
Roosevelt in 1906, the FDA started as the Pure Food and Administration Act under the 
Bureau of Chemistry of the Department of Agriculture in response to multiple complaints 
of contaminated food and water. Now, the FDA regulates over 2 trillion dollars’ worth of 
food, consumer goods, and drugs, including the phenylbutyrate drug that is being 
explored in this thesis (Hamburg & Sharfstein, 2009; Schacter, 2006).  
The FDA began in the early 1900s after a wave of medical malpractices in the late 
1800s made it clear that there needed to be some form of government regulation over 
drugs available to the public market. Before drug regulations existed, pharmaceutical 
companies produced drugs laced with cocaine, opium, and alcohol, or sold products that 
were diluted down to ineffective doses. Unknowing physicians and pharmacies would 
then prescribe these products to their patients, unaware of the harmful side effects the 
drugs would produce (Schacter, 2006). In response to the tragic deaths of the diethylene 
glycol poisoning in 1937 from physician-prescribed drugs, the Federal Food, Drug, and 
25 
 
Cosmetic Acts was passed in 1938. This gave the U.S. government the authority to 
regulate contents of new drugs before they entered the market (Rägo & Santoso, 2008). 
For the first time, the government was overseeing drug distribution.  
But even under early federal regulation, drug safety still posed a problem. The red 
clauses of patent laws protected pharmaceutical companies from legal consequences from 
their false drug advertisements (Schacter, 2006). Furthermore, drugs were still released 
into the public before thorough screening, leading to catastrophic events like the 
thalidomide-induced birth defects in 1956, a case where pregnant mothers were given 
thalidomide as a form of anti-anxiety medication, only to find that the pills caused the 
mothers to give birth to over 10,000 crippled babies shortly after (Rägo & Santoso, 
2008). The government was trying to establish a foundation for drug review, but their 
review process was still hasty and hindered by a desire to produce more drugs. It was not 
until after several more years of disease outbreaks, severe reactions, fatalities, and birth 
abnormalities that the U.S. government passed the Drug Amendments Act of 1962, 
declaring that all new drugs entering the market will be subjected to a long-term review 
process. (Rägo & Santoso, 2008; Schacter, 2006; Stepp, 1999).  
Still, the 1962 Drug Amendment Act did not finalize the drug review system; the 
FDA continued to refine their drug review process to keep up with modern changes in 
drug production. In 1997, the United States government passed the FDA Modernization 
Act, which made the screening process even more rigorous for companies that wanted to 
introduce new drugs to the public. While the 1962 Drug Amendment Act allowed drugs 
into the public after a few months of review, the FDA Modernization Act demanded an 
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average of 12 years, multiple phases, and multiple review cycles to get FDA approval for 
a new drug. With each phase of the review process, the percentage of drugs moving on to 
the next stage decreases (Ross, Dzara, Downing, 2015; Schacter, 2006).  
The first step of getting FDA approval for a potential drug, while time consuming 
and costly, is just the beginning. After discovery of a potential drug in the laboratory—
which itself can take multiple years—the researcher must make the decision to develop 
the drug as a marketable item in the future. Here, the researcher must find sponsors, 
grants, or other sources of funding, sometimes costing up to hundreds of thousands of 
dollars, for further laboratory and animal testing of the drug to determine the safety of the 
drug, the dosage which it is most useful, and the efficacy of the drug. (Adams & 
Brantner, 2006; Schacter, 2006). At this point, the drug has not left the laboratory. 
After the results of the first stage have been reviewed multiple times by the 
government and review boards, the drug moves onto clinical human testing, which is 
composed of 3 phases. Phase 1 of clinical trials tests whether the drug has negative 
effects in the human body, how quickly the drug enters and leaves the human body, and 
how effectively does the drug act on its targeted cells (Schacter, 2006). Basically, this 
steps translates the results found in the animal testing stages into a dosage and schedule 
that is appropriate for human patients. Then, we move into Phase 2 of clinical trials, 
where we start to see double blind trials, randomization, and more targeted populations of 
the drug used in controlled studies. This a process is a continuation of Phase 1, and can 
take from several months to several years to complete (Schacter, 2006). Finally, Phase 3 
of clinical trials are long-term studies of the drug, where the number of participants are 
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often increased to the hundreds or thousands, the selections are more randomized, and the 
experiments are even more extensively controlled. On average, this phase lasts 5 years 
and can cost up anywhere from hundreds of thousands to millions of dollars (Adams & 
Brantner, 2006; Schacter, 2006).  
At last, the drug proposal can be submitted to the FDA for review, supported by 
years of research, hundreds of data sheets, and an average investment of 800 million 
dollars per drug (Schacter, 2006). Even so, most drug proposals will be sent back for 
another round of revision on the basis of insufficient data, safety concerns requiring 
additional analysis, unsatisfactory marketing and distribution plans, or inadequate drug 
labels/consumer information sheets (Ross, Dzara, Downing, 2015). 17% of returned drug 
proposals are approved within 3 years and 47% are approved within 10 years (Patridge, 
Gareiss, Kinch & Hoyer, 2015). Unfortunately, only 20% of the drugs entering Phase 1 of 
clinical trials ultimately get used by the public (Schacter, 2006). 
 
Efficacy of FDA drug regulation—An analysis. 
Given the increasingly lengthy review process, the practicality of the FDA has 
grown controversial, criticized for hindering the productivity of drug research and 
development. Still, the chief purpose of the FDA is still to protect its people from 
exploitation by pharmaceutical companies or from accidental side effects of poorly 
developed drugs. For one, side effects of novel drugs may not manifest right away as 
some drugs take longer to metabolize and integrate itself into the body’s system (Lesser, 
Fahn, Snider, Cote, Isgreen & Barrett, 1979). Many drugs require constant dosages to 
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build up a large enough chemical gradient to change the way an organ system is 
behaving. If we only relied on data from short-term studies, we potentially dismiss 
promising drugs that benefit the patient in the long-run, but do not show any immediate 
results. Vice versa, if the drug is not acting where it is intended or if it is causing as 
overreaction in its targeted system, we would not know how the body would truly react 
until much later on when the drug has accumulated to dangerous levels inside the body.  
For example, L-DOPA can improve motor impairments in some Parkinson’s 
patients, but intensify the severity of the same motor impairments in others. However, 
after a few years of L-DOPA use, some of the same patients who originally benefited 
from L-DOPA develop dramatic side effects to the drug while others largely remained 
unchanged (Lesser, Fahn, Snider, Cote, Isgreen & Barrett, 1979). All of these factors 
influence the efficacy of drugs, translating into changes in drug dosages, drug schedules, 
and drug regimen—components which are monitored and adjusted in Phases 2 and 3 of 
Clinical Trials during the FDA approval process (Schacter, 2006). In these cases, short-
term data is too narrow. We have to know that a drug will improve a majority of the 
public’s conditions and these improvements outweigh the potential risks that the drugs 
cause. It is nearly impossible to fully capture the benefits and harms of novel drugs 
without years of extensive observation. 
On the other hand, since the FDA’s introduction, the culture of drug research and 
development has shifted. In 1962, the number of new chemical entities entering the 
public market dropped by nearly half and continued to gradually decline over several 
decades (Thomas, 1990). With the increasing number of regulations by the FDA, drugs 
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are forced to stay in the research and development phase longer than ever before, costing 
pharmaceutical researchers more money to develop and delay the monetary rewards for 
their long years of research. In the U.S., an estimated 820 million dollars was invested by 
companies into drug research and development in the 1990s, a number projected to 
increase in the 21st century (Schacter, 2006).  
In terms of Parkinson’s disease research, the National Parkinson’s Disease 
Foundation—one of the many large organizations funding Parkinson’s disease research—
has invested over $115 million since they were founded in 1957 (Parkinson’s Disease 
Foundation, 2017). Another big supporter, the Michael J. Fox Foundation, has funded 
more than $650 million dollars since 2000 to search for a cure (Michael J. Fox 
Foundation). These are, of course, the funding giants in Parkinson’s disease research; the 
numbers do no justice to the amount of money invested by private donors, researchers, 
and family members of those suffering from Parkinson’s disease. Research is costly.  
With costs in the millions, the means for research is often dominated by big firms 
and corporations. Individual researchers and university affiliates have to apply for 
government funding or request sponsorship from wealthy donors in order to sustain their 
drug research. I, myself, have had to apply for multiple grants for my research projects 
and I have watched two different small labs shut down from lack of funding. The hunt for 
funding is greatly stressful and markedly hinders research progress. Under the FDA 
reform, small players in the pharmaceutical industry are at a disadvantage; the system 
becomes exclusive to those who can afford the investment rather.  
Even within big corporations and governmental funding, the chances of producing 
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a successful drug are slim. There are thousands of drug proposals every year, but only a 
limited amount of funding available. Thus, companies and government grant programs 
are forced to screen for which potentially successful drugs, discarding less promising 
projects at an early stage (Schacter, 2006). As mentioned previously, early estimates of a 
drug’s efficacy are inaccurate. But because each project needs sufficient funding to 
progress into late clinical trials, in-depth analyses of many potential drugs cannot afford 
to be explored. In an unforgiving cycle, drug research needs to be funding for reliable 
results, but conversely, there needs to be reliable results for funding. Under this system, 
the productivity of drug research is hindered, shackled by desires for profit. 
Hand in hand with decreased novel drug production, more people with severe 
illnesses are denied potentially life-changing treatment. On average, the FDA approved 
50 new drugs every year from 1955 to 1960. However, this number dropped to an 
average of 17 a year between 1965 and 1970 (Gieringer, 1985). Although these numbers 
are steadily decreasing in the 21st century, novel drug shortages are still a relevant 
concern (Eichler, Pignatti, Flamion, Leufkens, & Breckenridge, 2008). If a new drug 
saves 1,000 lives per year, a delay in its introduction would result in 1,000 deaths every 
single year that the drug is withheld from the market. In 2005, the World Health 
Organization projected that chronic illnesses will be responsible for 41 million deaths in 
2015 if these illnesses are not controlled appropriately (Abegunde, Mathers, Adam, 
Ortegon, Strong, 2007). Without intervention, these numbers will not change.  
Even in less fatal illnesses, people living with mental impairments, physical 
handicaps, or any type of impaired functioning are still subjected to the effects of their 
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diseases until treatment is available. In end-stage Parkinson’s disease, patients begin to 
suffer the effects of mental deterioration as they start to lose the ability move on their 
own, care for themselves, and recall their loved ones (Aarsland et al., 2004). In fact, these 
mental deficits, paired with the chronic motor impairments, extensively interfere with a 
patient’s quality of life, often resulting in a high prevalence of depression and other 
mental illnesses (Cummings, 1992). Without adequate treatment, quality of life will still 
decline physically, mentally, and emotionally. Right now, there is an astounding amount 
of research dedicated to finding treatment for chronic illnesses like Parkinson’s disease. 
However, many of these treatments will not be available to the public market for another 
several years to decades under the current FDA system (America’s BioPharmaceutical 
Research Companies, 2014; Schacter, 2006).  
Another contributing factor to patients’ quality of life are the long-term expenses 
of treating Parkinson’s disease from diagnosis to departure. Outside of the money spent 
on Parkinson’s disease research, Parkinson’s disease, on a macro level, costs the U.S. 
economy $60 billion for direct and indirect expenses in patient care, a value that will 
increase in 2020 if left unaddressed (America’s BioPharmaceutical Research Companies, 
2014). These costs include revenue lost from patients that are too sick to work and 
patients that require health benefits for their chronic conditions. On the micro level, a 
Parkinson’s disease patient spends an average of $2,500 medication treatment per year 
and an average of $100,000 therapeutic surgery costs once they enter the severe end 
stages of Parkinson’s disease (America’s BioPharmaceutical Research Companies, 2014). 
These out-of-pocket expenses contribute to the quality of life diagnosed patients can live. 
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We have a moral and social obligation to minimize death and suffering for as 
many people as possible. At the root of drug research is the desire to improve the 
conditions of mankind. In the past, efforts in drug development were corrupted by greed 
and power from pharmaceutical companies, calling the need for some form of drug 
regulation; however, trends in recent years suggest that over-regulation of drug 
development can also cripple drug research productivity as it denies drug access to 
people who urgently need it. As a prospective medical student and a student researcher, I 
have seen both the need for drug regulation as well as its complications. Particularly, my 
phenylbutyrate research with Dr. Freed has given me a more personal understanding of 
how FDA drug regulation impacts a new drug proposal.  
 
Phenylbutyrate in the Freed Lab 
The phenylbutyrate project started in the Freed Lab in 2006, discovered by a 
summer student studying the effects of histone deacetylase inhibitors on the DJ-1 gene. 
At the time, the neuroprotective effects of the DJ-1 gene had already been established and 
the lab was trying to find ways to increase DJ-1 gene production. During the process of 
protein expression, DNA is copied into strands of RNA, which are then used as templates 
to generate proteins that the cell can use. When the cell is not making new proteins, DNA 
strands are wrapped around histone proteins. In order for protein production to start, 
DNA strands must acetylate and uncoil from the histone proteins before it can be copied 
into strands of RNA. Histone deacetylase inhibitors encourage the acetylation and 
uncoiling of the DNA strands from the histones, therefore promoting protein production 
33 
 
(Ryu et al., 2013). Of course, different histone deacetylase inhibitors target different 
genes and different histones, which was why finding the right histone deacetylase 
inhibitor to target the DJ-1 gene was necessary. 
Out of all the histone deacetylase inhibitors tested, phenylbutyrate was the most 
effective at increasing cellular levels of DJ-1 (Freed, 2016). These DJ-1 increases were 
even further amplified when the cells were treated with both phenylbutyrate and 6-
hydroxydopamine to induce stress in the cells. Eventually, this evolved into extensive 
tissue culture and rat studies whose results were published by Zhou, Bercury, 
Cummiskey, Luong, Lebin, and Freed in 2011. By the time the 2011 was published, the 
Freed Lab had enough data to suggest that phenylbutyrate could be a promising treatment 
for Parkinson’s disease. And so, the drug continued into human clinical trials. 
When we started pursuing phenylbutyrate as an alternative treatment for 
Parkinson’s disease, the drug had already been FDA approved to treat urea cycle 
disorders and was marketed as Ravicti or Buphenyl (Freed, 2016; Leonard, 1995). Aside 
from the market cost of the drug, there were very little restrictions against us using 
phenylbutyrate for our experiments. Thus, getting approval to start phenylbutyrate 
clinical trials was relatively easy; the lab was exempt from the extensive FDA approval 
process and was instead allowed to move on after completing a smaller scale proposal. 
Basically, as long as the lab promised to not perform studies that will disprove its 
efficacy in urea cycle disorders, change the description of the drug on FDA-approved 
labels, and only use the drug at already approved doses or lower, we could largely bypass 
the FDA screening process (Freed, 2016; Schacter, 2006). In the end, getting FDA 
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approval to transition from bench work to clinical trials only took two weeks (Freed, 
2016). 
During Phase 1 of clinical trials, the Freed Lab focused on finding the side 
effects of phenylbutyrate. Forty participants between 40 and 75 years old were selected 
for this study, as Parkinson’s disease typically manifests in this age range. Participants 
were age matched between a group with existing Parkinson’s disease and a group without 
Parkinson’s disease diagnoses. Over three weeks, all 40 participates took daily 
phenylbutyrate pills at previously FDA-approved doses and monitored for side effects 
and reactions to the drugs (Freed, 2016). As it turned it turned out, because 
phenylbutyrate is a fatty oil substance, many people developed gastrointestinal side 
effects, such as stomach irritation, heartburn, nausea, and vomiting. Ten percent of the 
participants developed rashes. Fortunately, all of these side effects were consistent with 
FDA-published labels for Buphenyl, showing that using phenylbutyrate as a Parkinson’s 
disease treatment is not significantly harmful (Freed, 2016; Leonard, 1995). The studies 
were largely considered successful.  
  However, as the Freed Lab moved into Phase 2 of clinical trials, things became 
more complicated. Now, we were looking at phenylbutyrate dose tolerability in 
Parkinson’s patients. In Phase 2, we were trying to find a dose that will be the most 
effective long-term while producing the least amount of side effects in the patients. To do 
so, we implemented a double-blind system, using a fatty, oil-based placebo pill as a 
control. We then gave participants the maximum FDA-approved dose, two-thirds of the 
maximum FDA-approved dose, one-third of the maximum FDA-approved dose, or a 
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placebo pill that contained no drug at all and monitored the type and severity of the side 
effects each dosage produced (Freed, 2016). Neither the researchers in the Freed lab, our 
study coordinators, or the patients knew who received the phenylbutyrate treatment and 
who received a blank pill until the conclusion of the study.  
We are currently still in Phase 2 of clinical trials. Ideally, each participant will 
take these pills for one year from the time they enroll into the study. Given the 
commitment that the study requires (i.e. the constant check-ups, the secrecy and 
frustration of the double blind trials, and the potential side effects that both the placebo 
and the drug will have), we predict that 50% of the participants will drop out by the end 
of the study (Freed, 2016; Freed and Levay, 2002). Thus, to ensure that we have 
sufficient data by the end of the study for effective analyses, we have to start with a large 
enough population. We are hoping for 25 participants per group, 100 participants in all, 
with the expectation that we will have at least a dozen patients per group that are still 
participating by the end (Freed, 2016). 
 We started Phase 2 in early 2016. Currently, Gabrielle Lemicke, the coordinator 
for the study, is still interviewing participants from clinics across the United States for the 
first rounds of testing. She is reaching out to promising candidates, informing about the 
purposes of our study, and interviewing them, in a process that can take several months 
per patient. For the population size we want, recruitment will take an estimated 2 to 4 
years (Freed, 2016). As patients enroll into the study, we individually start them on their 
1-year phenylbutyrate course as we continue to recruit more potential participants and 
age-matching them to the participants we already have. The study as a whole will take the 
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Freed Lab an estimated 5 years if events unfold according to plan. We expect to have 
results by 2021 (Freed, 2016).  
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Reflections and Conclusions 
When I first read about the phases of clinical testing, I imagined that each phase 
was self-contained, conducted independently from the phase prior. Realistically, time and 
money does not allow for this type of separation. For one, I was surprised to find that 
recruitment for clinical trials took so long, stretching out to years and sometimes even 
decades for a drug trial that only lasts a year itself. When I was merely reading about 
clinical trials, I imagined that recruitment, initiation of treatment, data collection, and 
data analysis occurred sequentially and in clearly defined time frames. However, I now 
realize that many of these steps overlap to accommodate for participant preferences, 
recruitment difficulties, changes in participants’ health, technical issues, etc. Research 
with human participants is not as straight-forward as the textbook depicts.  
For example, in the case of phenylbutyrate testing in the Freed lab, Phase 2 of our 
clinical trials, in theory, should only take one year. After all, patients are only taking the 
drug for twelve months once they agree to participate in the study. Unfortunately, 
recruiting participants requires time to search for potential patients, money to fly out to 
meet the patients, and thoroughness to make sure that patients have well-informed 
consent. With the staggered enrollment, each participant will start and end their trial at 
different times and the study will not technically be finished until the last participant 
finishes his or her phenylbutyrate course, dragging out the clinical trials five times longer 
than the actual time needed to conduct the trial. In writing, these issues are simplified. 
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The textbook does no justice to the time and effort that is actually invested in conducting 
these clinical trials. 
 Secondly, what surprised me even more was how the bench work did not stop, 
even when clinical trials were taking off. Originally, I thought that a drug had to be 
finalized and perfected before it was handed off to the next stages of testing, like a baton 
in a relay race. From the way the FDA approval process was described in my books, I 
assumed that research teams would first devote 100% of their energy in cell and animal 
research, submit their research for approval, then redirect all of their energy into clinical 
testing once their proposals have been approved. In reality, this idea is extremely 
inefficient. Realistically, as a drug moves through clinical trials, researchers often choose 
to simultaneously continue their drug investigations in hopes of refining it, learning more 
about it, or finding a better substitute for it, so that clinical trials will have a higher 
chance of succeeding.  
 This is the case in the Freed Lab and, in fact, was the reason why this thesis 
project was possible. Although phenylbutyrate was halfway into its clinical trials, my 
colleagues and I were still working behind the scenes to try and identify its mechanisms. 
My project is one of many exploratory phenylbutyrate research. There are others in my 
lab that are looking at how phenylbutyrate is affecting mitochondria, how phenylbutyrate 
is changing cellular communication, etc. More specifically to the clinical trials, we are 
still feeding rats phenylbutyrate and observing cellular responses to phenylbutyrate 
treatment so that we can better understand how phenylbutyrate works in humans. If 
anything, my two years in the Freed Lab has taught me that science is less of a relay race 
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and more of a brick-building contest, open to modification by any of its team-members. 
There is just so much that I have learned in practice that the textbook has failed to fully 
capture. 
 
 In truth, phenylbutyrate still has a long way to go before it reaches the public as a 
treatment for Parkinson’s disease. As of 2016, 2 million dollars has been invested into the 
phenylbutyrate project, $600,000 of which from the Michael J. Fox Foundation, $400,000 
from individual sponsors, and $1 million from Dr. Freed himself, who truly believes that 
we can cure Parkinson’s disease within the next few decades. However, there is no doubt 
that this project will need more funding, more experiments, and more FDA reviews in 
phenylbutyrate’s future, before phenylbutyrate can change the world in the way that we 
envision. But for now, the Freed lab is grounded on the science, refining phenylbutyrate 
and expanding our scientific understanding of it. We are looking for new ways to explore 
the phenylbutyrate mechanism, to test its effects in Parkinson’s disease patients, and to 
detail its chemical actions in the body. The phenylbutyrate story, though started over a 
decade ago, is far from finished. 
My work in the Freed lab is, literally, quite small, focused on finding the 
molecular mechanism in which phenylbutyrate affects the Parkinson’s disease-fighting 
DJ-1 gene. When I joined the team, the phenylbutyrate project was already halfway into 
its clinical trials. The brick that I picked up from Dr. Freed had long been part of the 
mission to the cure for Parkinson’s disease, built from an idea created many years ago. 
And when I leave the lab, the building will surely continue until we have constructed an 
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answer. My only hope now is that the research that I have done—the brick that I have 
chiseled—has contributed in some meaningful way.  
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